Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$4.95 USD
-0.25 (-4.81%)
Updated May 20, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Monte Rosa Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 143 | 112 | 73 | 28 | 0 |
Income After Depreciation & Amortization | -143 | -112 | -73 | -28 | 0 |
Non-Operating Income | 8 | 4 | -1 | -8 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -135 | -109 | -74 | -36 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -135 | -109 | -74 | -36 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -135 | -109 | -74 | -36 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -137 | -109 | -71 | -27 | 0 |
Depreciation & Amortization (Cash Flow) | 6 | 4 | 2 | 1 | NA |
Income After Depreciation & Amortization | -143 | -112 | -73 | -28 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.40 | 47.23 | 25.00 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.63 | -2.30 | -2.96 | NA | NA |
Diluted Net EPS (GAAP) | -2.63 | -2.30 | -2.96 | NA | NA |
Fiscal Year end for Monte Rosa Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 1.06 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.06 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 36.02 | 34.87 | 36.97 | 37.23 | 34.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | -34.96 | -34.87 | -36.97 | -37.23 | -34.26 |
Non-Operating Income | 3.06 | 1.59 | 2.25 | 2.23 | 2.22 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -31.89 | -33.27 | -34.71 | -34.99 | -32.04 |
Income Taxes | 0.08 | -0.02 | 0.17 | 0.19 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -31.97 | -33.25 | -34.88 | -35.18 | -32.04 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -31.97 | -33.25 | -34.88 | -35.18 | -32.04 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 60.16 | 56.93 | 49.82 | 49.43 | 49.35 |
Diluted EPS Before Non-Recurring Items | -0.53 | -0.58 | -0.70 | -0.71 | -0.65 |
Diluted Net EPS (GAAP) | -0.53 | -0.57 | -0.70 | -0.71 | -0.65 |